MagAO-X and HST High-contrast Imaging of the AS209 Disk at Hα

The detection of emission lines associated with accretion processes is a direct method for studying how and where gas giant planets form, how young planets interact with their natal protoplanetary disk, and how volatile delivery to their atmosphere takes place. H α ( λ = 0.656 μ m) is expected to be the strongest accretion line observable from the ground with adaptive optics systems, and is therefore the target of specific high-contrast imaging campaigns. We present MagAO-X and Hubble Space Telescope (HST) data obtained to search for H α emission from the previously detected protoplanet candidate orbiting AS209, identified through Atacama Large Millimeter/submillimeter Array observations. No signal was detected at the location of the candidate, and we provide limits on its accretion. Our data would have detected an H α emission with F _H _α > 2.5 ± 0.3 × 10 ^−16 erg s ^−1 cm ^−2 , a factor 6.5 lower than the HST flux measured for PDS70 b. The flux limit indicates that if the protoplanet is currently accreting it is likely that local extinction from circumstellar and circumplanetary material strongly attenuates its emission at optical wavelengths. In addition, the data reveal the first image of the jet north of the star as expected from previous detections of forbidden lines. Finally, this work demonstrates that current ground-based observations with extreme adaptive optics systems can be more sensitive than space-based observations, paving the way to the hunt for small planets in reflected light with extremely large telescopes

Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC.

Germline genetic testing is now routinely recommended for patients with prostate cancer (PCa) because of expanded guidelines and options for targeted treatments. However, integrating genetic testing into oncology and urology clinical workflows remains a challenge because of the increased number of patients with PCa requiring testing and the limited access to genetics providers. This suggests a critical unmet need for genetic services outside of historical models. This review addresses current guidelines, considerations, and challenges for PCa genetic testing and offers a practical guide for genetic counseling and testing delivery, with solutions to help address potential barriers and challenges for both providers and patients. As genetic and genomic testing become integral to PCa care, developing standardized systems for implementation in the clinic is essential for delivering precision oncology to patients with PCa and realizing the full scope and impact of genetic testing